Table 2. Participants with CYP3A5 loss-of-function alleles observed.
Discovery cohort (n = 197) | Validation cohort (n = 160) | |
---|---|---|
rs776746 (*3) | ||
0 | 98 (49.8) | 88 (55.0) |
1 | 77 (39.1) | 59 (36.9) |
2 | 22 (11.2) | 13 (8.1) |
rs10264272 (*6) | ||
0 | 154 (78.2) | 119 (74.4) |
1 | 42 (21.3) | 39 (24.4) |
2 | 1 (0.5) | 2 (1.3) |
rs41303343 (*7) | ||
0 | 162 (82.2) | 126 (78.8) |
1 | 31 (15.7) | 34 (21.3) |
2 | 4 (2.0) | 0 (0) |
All 3 LoF alleles | ||
0 | 51 (25.9) | 33 (20.6) |
1 | 88 (44.7) | 92 (57.5) |
2 | 58 (29.4) | 35 (21.9) |
Data shown as n (%). LoF, loss of function.